Cheng Yu-Chen, Wang Yu-Ming, Lin Yun-Hsuan, Cheng Jen-Yu, Li Shau-Hsuan, Huang Yu-Chuen, Tsai Ming-Yen
Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan.
Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan.
Contemp Clin Trials Commun. 2022 Mar 20;27:100912. doi: 10.1016/j.conctc.2022.100912. eCollection 2022 Jun.
Oral mucositis (OM) is a common side effect of radiotherapy (RT) that can have severe implications in patients with head and neck cancer (HNC). Traditional Chinese medicine (TCM) formula is widely applied in treating OM, but little substantial evidence exists to clarify it effects. The study intends to determine whether the TCM-based prescription in treating HNC with RT can improve the OM when compared with RT alone.
A single-center, randomized, two-arm parallel-group, open-label controlled clinical trial will be conducted to determine whether the Zi-Yin-Liang-Ge-San (ZYLGS), which contains , , , , and combined with RT can improve the incidence and severity of OM. Two hundred participants will randomly 1:1 to receive at least 6 weeks of RT plus ZYLGS powder or control. The primary outcome measures are onset, gradation of OM (Common Terminology Criteria for Adverse Events v5.0), and oral pain (visual analogue scale). The secondary outcome measures include nutritional status, the EORTC Quality of Life Core Questionnaire and head and neck module. The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, serious adverse events, and blood and biochemical analysis will be recorded to evaluate the safety. Visits will be performed for each week during the RT treatment period and then 2 weeks in the follow-up period.
The study's result will provide a high-level evidence for TCM-based formulation for HNC patients with RT on the effect of OM prevention and management.
口腔黏膜炎(OM)是放射治疗(RT)常见的副作用,对头颈部癌(HNC)患者可能产生严重影响。中药配方广泛应用于治疗OM,但鲜有确凿证据阐明其疗效。本研究旨在确定与单纯放疗相比,基于中药的处方用于头颈部癌放疗患者时能否改善口腔黏膜炎情况。
将开展一项单中心、随机、双臂平行组、开放标签的对照临床试验,以确定含有[具体成分未列出]的滋阴凉膈散(ZYLGS)联合放疗能否改善口腔黏膜炎的发生率和严重程度。200名参与者将按1:1随机分组,分别接受至少6周的放疗加ZYLGS散剂或对照组治疗。主要结局指标为口腔黏膜炎的发病情况、分级(不良事件通用术语标准第5.0版)和口腔疼痛(视觉模拟评分)。次要结局指标包括营养状况、欧洲癌症研究与治疗组织生活质量核心问卷及头颈部模块。将记录患者报告的不良事件通用术语标准结局、严重不良事件以及血液和生化分析结果以评估安全性。在放疗治疗期间每周进行访视,随后在随访期每2周进行一次访视。
本研究结果将为基于中药的配方用于预防和管理头颈部癌放疗患者口腔黏膜炎的效果提供高级别证据。